A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
CompletedPhase 3Results postedLast updated 21 March 2022
What this trial tests
Phase 3 trial testing Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody in Squamous Non-Small Cell Lung Cancer in 1,021 participants. Completed in 17 February 2021.
18 and older, any sex, with Squamous Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) PopulationPrimary· Up to approximately 30 months after first participant enrolled
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
5.6
5.5 – 5.7
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
6.5
5.7 – 7.1
Arm A: Atezolizumab + Paclitaxel + Carboplatin
5.6
5.5 – 6.9
Overall Survival (OS) in the ITT PopulationPrimary· Up to approximately 39 months after first participant enrolled
OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
13.5
12.2 – 15.1
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
14.2
12.3 – 16.8
Arm A: Atezolizumab + Paclitaxel + Carboplatin
12.6
11.6 – 14.7
OS in the in the Teff PopulationSecondary· Up to approximately 39 months after first participant enrolled
OS is defined as the time between the date of randomization and date of death from any cause in the in the Teff Population.
Teff >=-1.91
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
16.4
12.2 – 19.7
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
17.4
12.3 – 23.8
Arm A: Atezolizumab + Paclitaxel + Carboplatin
15.2
13.4 – 22.8
Teff<-1.91
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
12.4
11.2 – 14.3
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
13.0
11.4 – 14.8
Arm A: Atezolizumab + Paclitaxel + Carboplatin
10.5
9.1 – 12.6
PFS as Determined by the Investigator Using RECIST v1.1 in the Teff PopulationSecondary· Up to approximately 30 months after first participant enrolled
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Teff Population.
Teff >=-1.91
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
5.6
5.1 – 5.7
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
7.0
5.5 – 8.5
Arm A: Atezolizumab + Paclitaxel + Carboplatin
7.0
5.6 – 9.7
Teff<-1.91
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
5.7
5.5 – 6.6
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
6.2
5.6 – 7.0
Arm A: Atezolizumab + Paclitaxel + Carboplatin
5.5
4.5 – 5.6
PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 PopulationSecondary· Up to approximately 30 months after first participant enrolled
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population.
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
5.6
5.1 – 5.7
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
8.4
6.8 – 10.4
Arm A: Atezolizumab + Paclitaxel + Carboplatin
7.0
5.6 – 8.3
PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 PopulationSecondary· Up to approximately 30 months after first participant enrolled
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the TC1/2/3 or IC1/2/3 Population.
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
5.6
5.3 – 5.7
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
7.1
5.8 – 8.3
Arm A: Atezolizumab + Paclitaxel + Carboplatin
7.0
5.6 – 8.3
OS in the TC2/3 or IC2/3 PopulationSecondary· Up to approximately 39 months after first participant enrolled
OS is defined as the time between the date of randomization and date of death from any cause, in the TC2/3 or IC2/3 Population.
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
14.5
12.1 – 17.2
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
20.4
13.8 – 24.1
Arm A: Atezolizumab + Paclitaxel + Carboplatin
14.8
11.1 – 23.7
OS in the TC1/2/3 or IC1/2/3 PopulationSecondary· Up to approximately 39 months after first participant enrolled
OS is defined as the time between the date of randomization and date of death from any cause in the TC1/2/3 or IC1/2/3 Population.
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
15.0
12.4 – 17.2
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
14.8
12.1 – 19.6
Arm A: Atezolizumab + Paclitaxel + Carboplatin
14.9
12.5 – 18.2
Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT PopulationSecondary· Up to approximately 30 months after first participant enrolled
Proportion of participants with an objective response (CR or PR) in the ITT population.
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
41.0
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
49.7
Arm A: Atezolizumab + Paclitaxel + Carboplatin
49.3
Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT PopulationSecondary· Up to approximately 30 months after first participant enrolled
Duration of response is defined as the time from the first documented objective response to documented PD or death from any cause, whichever occurred first, in the ITT Population.
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
5.2
4.4 – 5.6
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
7.2
6.8 – 9.5
Arm A: Atezolizumab + Paclitaxel + Carboplatin
7.0
5.7 – 8.3
Event Free Rate at 1 and 2 Years in the ITT PopulationSecondary· 1 and 2 years
Event free rate at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population.
1 Year
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
56.28
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
56.34
Arm A: Atezolizumab + Paclitaxel + Carboplatin
52.30
2 Year
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
26.58
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
32.51
Arm A: Atezolizumab + Paclitaxel + Carboplatin
27.79
Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT PopulationSecondary· Up to approximately 30 months after first participant enrolled
TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population. The EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC scales and single-item measures will be linearly transformed so that each score has a range o
Group
Value
95% CI
Arm C: Nab-Paclitaxel + Carboplatin
3.2
2.6 – 4.1
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
4.2
3.2 – 5.6
Arm A: Atezolizumab + Paclitaxel + Carboplatin
3.0
2.6 – 3.9
Adverse events — posted to ClinicalTrials.gov
Time frame: From the first study drug administration to the data cutoff date: 17 February 2021 (up to approximately 68 months)..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Arm C: Nab-Paclitaxel + Carboplatin
Serious: 96/334 (29%)
Deaths: 252/340
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Squamous Non-Small Cell Lung Cancer
Currently open trials in the same condition.
NCT05123482 — A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
· Phase 1, PHASE2
· recruiting
Other Hoffmann-La Roche trials
Trials by the same sponsor.
NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O
· Phase 2
· not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in
· Phase 3
· recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations
· not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
· Phase 3
· recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric
· Phase 3
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 21 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02367794.